stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Revenue growth
Revolution Medicines, Inc.'s revenue growth over the twelve months to 30 September 2026 was 491.1%, up 558.4 percentage points from fiscal 2023 (−67.3%). Over the past ten years it has ranged from −67.3% (fiscal 2023) to 148.2% (fiscal 2019) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2023 | −67.3% | (87.65) |
| FY2022 | 20.4% | 52.00 |
| FY2021 | −31.6% | (17.52) |
| FY2020 | −14.1% | (162.26) |
| FY2019 | 148.2% | 207.86 |
| FY2018 | −59.7% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 1,188.7% | 1,266.60 |
| Dec 2023 | −77.9% | (19.84) |
| Jun 2023 | −58.1% | (50.61) |
| Mar 2023 | −7.44% | (69.49) |
| 16 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. | 491.1% |
| INSM Insmed, Inc. compare | 240.0% |
| ARGX argenex SE compare | 60.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 32.9% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| RPRX Royalty Pharma PLC compare | 11.4% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement